Form 4: Decheng Capital Sells BeyondSpring Shares

Decheng Capital entities and Dr. Xiangmin Cui reported sales of BeyondSpring Inc. ordinary shares totaling 153,816 shares over three days in October 2025.

Summary

• Decheng Capital China Life Sciences USD Fund III, L.P., a 10% owner and director affiliate of BeyondSpring Inc. (BYSI), reported sales of ordinary shares.
• On October 13, 2025, 107,361 ordinary shares were sold at a weighted average price of $1.70 per share, ranging from $1.69 to $1.75.
• On October 14, 2025, an additional 28,495 ordinary shares were sold at a weighted average price of $1.65 per share, ranging from $1.62 to $1.70.
• On October 15, 2025, 17,960 ordinary shares were sold at a weighted average price of $1.65 per share, ranging from $1.60 to $1.685.
• These transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.
• Following these transactions, Decheng Capital China Life Sciences USD Fund III, L.P. beneficially owns 1,650,204 ordinary shares.
• Decheng Capital China Life Sciences USD Fund II, L.P. beneficially owns 1,617,409 ordinary shares.
• Decheng Capital Global Healthcare Fund (Master), LP beneficially owns 891,734 ordinary shares.
• The total number of shares sold across these three days is 153,816.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling by a major shareholder and director affiliate. While the sales were pre-planned under a 10b5-1 agreement, the reduction in stake by a knowledgeable insider can still be interpreted as a bearish signal for the stock.

Positives

• The sales were conducted under a Rule 10b5-1 plan, indicating a pre-arranged transaction rather than a reaction to immediate negative news, which may mitigate some negative market sentiment.

Negatives

• Insider selling by a significant shareholder and director affiliate (Decheng Capital entities and Dr. Xiangmin Cui) can be perceived negatively by the market, potentially signaling reduced confidence in the company's near-term prospects or that the stock is fully valued.

Risks

• The market may interpret the insider sales as a lack of confidence from a major shareholder and director, potentially leading to downward pressure on BeyondSpring Inc.'s stock price.
• The sales could be a precursor to further divestment by Decheng Capital, which might create an overhang on the stock.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding BeyondSpring Inc.'s future performance or strategic direction.

Management Comments

• Dr. Xiangmin Cui, manager of the general partners for the Decheng Capital funds, signed the filing, indicating his involvement in the beneficial ownership and transactions.

Industry Context

Insider selling, particularly by a significant institutional investor and director, can be viewed by the market as a signal regarding the company's valuation or future prospects. While these sales are under a pre-arranged 10b5-1 plan, they still represent a reduction in a major insider's stake in BeyondSpring Inc. This action is specific to the reporting person's portfolio management and does not directly reflect broader industry trends, though it could influence investor sentiment within the biotechnology or pharmaceutical sector where BeyondSpring operates.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• No litigation or regulatory matters were mentioned in this filing.

Related Party Transactions

• The reported sales of ordinary shares were conducted by Decheng Capital entities, which are affiliated with Dr. Xiangmin Cui, a director and 10% owner of BeyondSpring Inc. These transactions are considered related-party dealings.

Stakeholder Impact

• Shareholders may view the insider selling by a major institutional investor and director affiliate as a negative indicator, potentially leading to decreased investor confidence and downward pressure on the stock price.
• The transactions do not directly impact employees, customers, suppliers, or creditors as they relate solely to beneficial ownership changes.

Next Steps

• NA

Key Dates

Recommendation

The insider sales by Decheng Capital, a significant shareholder and director affiliate, are generally a negative signal. However, the transactions were executed under a Rule 10b5-1 plan, indicating they were pre-scheduled and not a reaction to recent adverse events. This mitigates some of the immediate negative implications. Given the planned nature of the sales and without additional information on the company's fundamentals or other market catalysts, a 'hold' recommendation is appropriate, advising investors to monitor future developments and the company's performance closely.

Keywords

BeyondSpring, BYSI, Decheng Capital, insider trading, Form 4, stock sale, beneficial ownership, director, 10% owner, Rule 10b5-1